Long-Acting Injectable Drug Prevents HIV Among Men Who Have Sex with Men and Transgender Women

An investigational long-acting form of the HIV drug cabotegravir injected once every 8 weeks safely and effectively prevents HIV acquisition in men who have sex with men and transgender women who have sex with men.